Trial Profile
A Phase 2, Open-Label, Multi-Center Study to Assess Safety and Efficacy of Second/Third-Line Treatment With NAB-Paclitaxel (ABI-007) In Combination With Epigenetic Modifying Therapy Of CC-486, Or Immunotherapy of Durvalumab (MEDI4736), Or As Monotherapy In Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC): Abound.2L+
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Durvalumab (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms abound2L+
- Sponsors Celgene Corporation
- 07 Sep 2023 Status changed from active, no longer recruiting to completed.
- 14 Mar 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 24 Jan 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.